Compositions and methods of delivery of pharmacological agents

Abstract

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the pharmaceutically acceptable carrier comprises deferoxamine in an amount effective to inhibit microbial growth in the pharmaceutical composition. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, anesthetics, antimicrotubule agents, agents to treat cardiovascular disorders, antihypertensives, anti-inflammatory agents, anti-arthritic agents, antiasthmatics, analgesics, vasoactive agents, immunosuppressive agents, antifungal agents, antiarrhythmic agents, antibiotics, and hormones. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the pharmaceutical agent is selected from the group consisting of paclitaxel, docetaxel, taxanes, camptothecin, propofol, amiodarone, cyclosporine, rapamycin, amphotericin, liothyronine, epothilones, colchicines, thyroid hormones, vasoactive intestinal peptide, corticosteroids, melatonin, tacrolimus, mycophenolic acids, and derivatives thereof. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the pharmaceutical agent is propofol. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is a liquid and comprises from about 0.1% to about 25% by weight of albumin. 
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein the pharmaceutical composition comprises about 0.5% to about 5% by weight of albumin. 
     
     
         7 . The pharmaceutical composition of  claim 5 , wherein the pharmaceutical composition is dehydrated. 
     
     
         8 . The pharmaceutical composition of  claim 6 , wherein the pharmaceutical composition is lyophilized. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition comprises a mesylate salt of deferoxamine. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the pharmaceutical composition is a liquid and comprises from about 0.0001% to about 0.5% by weight of deferoxamine mesylate. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the pharmaceutical composition comprises about 0.1% by weight of deferoxamine mesylate. 
     
     
         12 . The pharmaceutical composition of  claim 10 , wherein the pharmaceutical composition is dehydrated. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the pharmaceutical composition is lyophilized. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is an oil-in-water emulsion. 
     
     
         15 . The pharmaceutical composition of  claim 5 , wherein the pharmaceutical agent is propofol. 
     
     
         16 . The pharmaceutical composition of  claim 10 , wherein the pharmaceutical agent is propofol. 
     
     
         17 . The pharmaceutical composition of  claim 9 , wherein the pharmaceutical agent is propofol, the propofol is present in an amount from about 0.1% to about 5% by weight, the albumin is present in an amount from about 0.1% to about 25% by weight, and the deferoxamine mesylate is present in an amount from about 0.0001% to about 0.5% by weight.